Physician profile
Mary E Ostaszewski
NPI 1003013236
$699.71
in general payments reported to CMS, 2019-2025
11 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $210 · 2023: $85.24 · 2024: $53.34 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.96 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $210.38 | 2021 | |
| Baxter Healthcare | $210.38 | 2022 | |
| Astellas Pharma US INC | $65.99 | 2023 | |
| Lilly USA, LLC | $36.44 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $36.38 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $36.20 | 2025 | Rybelsus, Ozempic |
| Amgen INC. | $33.06 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $20.04 | 2025 | Shingrix, Arexvy |
| Dexcom, INC. | $19.36 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $16.96 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $14.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ostaszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.